Lupin Launches Dapaturn GM Range for Improved Approach to Manage Type 2 Diabetes - Video

Published On 2024-01-01T11:45:36+05:30 | Updated On 17 Aug 2024 11:32 AM IST

Overview

Global pharma major Lupin Limited announced the launch of Dapaturn GM Forte for the treatment of diabetic patients in India.

Lupin's Dapaturn GM™ Forte are fixed-dose combination (FDC) tablets that contain three powerful ingredients - Dapagliflozin, Glimepiride, and Metformin (Extended Release). These ingredients work together to lower blood sugar levels, prevent weight gain, and safeguard the heart and kidneys.

Dapagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2), impedes the reabsorption of glucose in the kidneys, promoting its excretion in the urine. This helps to lower blood sugar levels and reduce the risk of kidney damage.

Glimepiride, a sulfonylurea, stimulates the pancreas to boost insulin production and lowers cell resistance to insulin. This dual action aids in lowering blood sugar levels and preventing diabetes-related complications.

Metformin, a biguanide, reduces glucose production in the liver and enhances cell sensitivity to insulin, effectively lowering blood sugar levels and preventing weight gain.

Dapaturn GM™ Forte FDCs have received approval from the Drug Controller General of India (DCGI), attesting to their safety and efficacy in the treatment of type 2 diabetes mellitus. They are available in two strengths:

Dapaturn GM™ Forte contains Dapagliflozin 10 mg, Glimepiride 1 mg or 2 mg, and Metformin HCl 1000 mg ER.

What sets Lupin’s Dapaturn GM™ and Dapaturn GM™ Forte apart is the incorporation of a unique feature - the ‘Humrahi’ QR code. By scanning this code, users can gain access to ‘Humrahi’, an app and web-based patient support program providing personalized assistance to patients throughout their diabetes journey. This includes valuable tips, reminders, education, and motivation to help effective diabetes management.

Mr. Rajeev Sibal, President India Region Formulations, Lupin said, “With Dapaturn GM Range, we aim to provide our doctors and diabetic patients a powerful solution in a single pill, promising long-term benefits. We believe that the Dapaturn GM Range can significantly enhance the quality of life and self-assurance of diabetic patients in India.”

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Lupin Limited.

Speakers

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

MD Brand Connect

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751